---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Aug 1, 2008 at 4:32 PM
Subject: Magnetic resonance imaging for monitoring the effects of thalidomide on experimental human breast cancers.
To: mesothelioma77@gmail.com
[1]Eur Radiol. 2008 Jul 30;
Cyran CC, Sennino B, Chaopathomkul B, Fu Y, Rogut VS, Shames DM, Wendland MF, McDonald DM, Brasch RC
Thalidomide, which inhibits angiogenesis in certain tumor types, reduced extravasation of a macromolecular contrast medium (MMCM) in a human breast cancer model as assayed by MMCM-enhanced dynamic magnetic resonance imaging (MRI) and fluorescence microscopy in the same tumors. After a 1-week, three-dose course of thalidomide, the mean MRI-assayed endothelial transfer coefficient, K(PS), decreased significantly (p
___
Source: http://www.hubmed.org/display.cgi?uids=18665367
--
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Aug 1, 2008 at 4:32 PM
Subject: Magnetic resonance imaging for monitoring the effects of thalidomide on experimental human breast cancers.
To: mesothelioma77@gmail.com
[1]Eur Radiol. 2008 Jul 30;
Cyran CC, Sennino B, Chaopathomkul B, Fu Y, Rogut VS, Shames DM, Wendland MF, McDonald DM, Brasch RC
Thalidomide, which inhibits angiogenesis in certain tumor types, reduced extravasation of a macromolecular contrast medium (MMCM) in a human breast cancer model as assayed by MMCM-enhanced dynamic magnetic resonance imaging (MRI) and fluorescence microscopy in the same tumors. After a 1-week, three-dose course of thalidomide, the mean MRI-assayed endothelial transfer coefficient, K(PS), decreased significantly (p
___
Source: http://www.hubmed.org/display.cgi?uids=18665367
--
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc